[Executive functions in children with phenylketonuria: variations as a function of phenilalanine plasm level]

Leandro Fernandes Malloy-Diniz1, Cláudia Cardoso-Martins, Karina Cunha Carneiro

  • 1Núcleo de Neurociências e Análise Experimental do Comportamento do Curso de Psicologia, Faculdade Metropolitana, Belo Horizonte, MG, Brasil.

Insights

Children with high phenylalanine levels in Phenilketonuria (PKU) show executive function deficits. This study highlights the impact of phenylalanine on cognitive development in infants with PKU.

Area of Science:

  • Neuroscience
  • Developmental Psychology
  • Metabolic Disorders

Context:

  • Phenilketonuria (PKU) is a rare genetic disorder requiring early and continuous treatment.
  • Elevated phenylalanine levels can impact brain development.
  • Executive functions are crucial for cognitive control and behavior.

Purpose:

  • To investigate executive function deficits in infants with Phenilketonuria (PKU).
  • To determine if high phenylalanine levels are associated with specific cognitive impairments in PKU patients.

Summary:

  • This study compared 9-month-old infants with PKU (divided into low and high phenylalanine groups) to healthy controls.
  • While global mental development was similar across groups, infants with PKU and phenylalanine levels between 360-600 mmol/l performed significantly worse on executive function tasks.
  • This suggests a specific executive function deficit linked to higher phenylalanine levels in early PKU.

Impact:

  • Findings indicate that elevated phenylalanine levels in early childhood PKU may specifically impair executive functions.
  • This research underscores the importance of maintaining optimal phenylalanine control for cognitive development in infants with PKU.
  • Results may inform therapeutic strategies and monitoring protocols for children with PKU.

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...